Exelixis Dividend

Dividend criteria checks 0/6

Exelixis does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.9%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per shareUS$0.70
Dividend yield forecast in 3Y0%

Recent dividend updates

No updates

Recent updates

Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Apr 22
Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Mar 28

We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Feb 26
We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Jan 17

Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Dec 27
Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

May 30
An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

Exelixis initiated at outperform at JMP Securities on cash flow, Cabometyx franchise

Oct 18

Exelixis: Efforts Continue To Diversify The Pipeline

Sep 15

Exelixis, Teva fight over Cabometyx generic again

Sep 06

Exelixis Needs To Move Away From Its Overdependence On Cabozantinib

Aug 03

Exelixis again sues MSN Pharmaceuticals over Cabometyx generic

Jul 19

Exelixis to pay Ryvu $3M upfront in license deal to develop targeted cancer drugs

Jul 07

Exelixis: Becoming A Giant Pharma

May 18

Exelixis: Beyond The Cabozantinib Franchise

Apr 21

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if EXEL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EXEL's dividend payments have been increasing.


Dividend Yield vs Market

Exelixis Dividend Yield vs Market
How does EXEL dividend yield compare to the market?
SegmentDividend Yield
Company (EXEL)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.8%
Industry Average (Biotechs)2.9%
Analyst forecast in 3 Years (EXEL)0%

Notable Dividend: Unable to evaluate EXEL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EXEL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate EXEL's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as EXEL has not reported any payouts.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.